



Market Announcement

6 February 2025

Arovella Therapeutics Limited (ASX: ALA) – Trading Halt

Description

The securities of Arovella Therapeutics Limited ('ALA') will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 10 February 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

6 February 2025

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne) ASX
Compliance Pty Ltd
Level 4, Rialto North Tower 525
Collins Street
Melbourne VIC 3000

BY EMAIL to: melissa.kostopoulos@asx.com.au & tradinghaltsmelbourne@asx.com.au

Dear Melissa

REQUEST FOR TRADING HALT

Arovella Therapeutics Limited (ASX: ALA) (the Company) requests a halt to the trading of the Company's quoted securities on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1, effective from commencement of trading today, 6 February 2025.

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations, as the Company expects to make a material update announcement to the market in connection with the capital raising placement announced on 10 January 2025.
2. The Company requests that the trading halt remain in place until the earlier of commencement of normal trading on 10 February 2025 or when the announcement is released to the market. The Company expects to make the announcement to the market before the commencement of normal trading on 10 February 2025.
3. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

This request has been authorised by the Board of Arovella Therapeutics Limited.

Kind regards



Tim Luscombe

Company Secretary & CFO

Arovella Therapeutics Limited